Circulating RNAs as new biomarkers for detecting pancreatic cancer

Table 2 Other circulating non-coding RNAs detected in cancer patients

Target candidate	Up/down	Cancer type	Sample	Number of patients	Extraction method	Quantification method	Normalization	Target selection	Ref.
Small ncRNA
SNORD33/66/76	Up	Lung	Plasma	37 Ca, 26 HR, 22 HC	mirVana miR isolation kit	SYBR qRT-PCR	U6 snRNA	mA	[93]
piR-651	Up	Gastric	Whole blood	93 Ca, 32 HC	TRizol	SYBR qRT-PCR	U6 snRNA	Pre	[94]
piR-823	Up
U2snRNA	Up	Pancreatic	Serum	80 Ca, 129 HC	mirVana miR isolation kit	qRT-PCR	cel-miR-54	mA	[84]
U2snRNA	Up	Colorectal		132 Ca, 129 HC
U2snRNA	Up	Lung	Serum	62 Ca, 51 BT, 45 HC	miRNeasy mini kit	LNA qRT-PCR	cel-miR-39	mA	[96]
U2snRNA	Up	Ovarian	Serum	119 Ca, 35 HC	mirVana PARIS kit	qRT-PCR	cel-miR-54	mA	[97]
Long ncRNA
H19	Up	Gastric	Plasma	43 Ca, 34 HC	N/A	pre-amplification qRT-PCR	N/A	Pre	[107]
MALAT1	Up	Prostate	Plasma	87 Ca, 82 HR, 23HC	mirVana PARIS kit	Taqman	Input amount	Pre	[108]
HULC	Up	Hepato-cellular	Plasma	30 Ca, 20 HC	TRIzol	qRT-PCR	GAPDH	Pre	[110]
TUG1 lincRNA	Up	Multiple myeloma	Plasma	62 MM, 40 HC	TriPure	qRT-PCR	GAPDH	Pre	[111]
LincRNA-p21	Down	CLL		68 CLL, 40 HC

Reference were searched in PubMed using the following search terms: “cancer”, “non-coding RNA”or “snoRNA” or “snRNA” or “piRNA” or “lncRNA”, and “circulating” or “serum” or “plasma” or “blood”. lincRNA: Long intergenic noncoding RNA; CLL: Chronic lymphocytic leukemia; MM: Multiple myeloma; Ca: Cancer patients; BT: Benign tumor; HR: High-risk patients; HC: Healthy control; N/A: Not available; Taqman: Taqman qRT-PCR; Pre: Previously reported in cancer tissue; mA: MiRNA microarray.